Brain Key, Inc.

BrainKey operates at the intersection of AI-based medical imaging, digital health, neuroscience, and longevity. Its stated product combines MRI analysis with biomedical and genetic inputs, then presents results through a personal 3D brain dashboard, brain-age calculations, population-referenced volume profiling, and lifestyle recommendations. That combination distinguishes it from narrower radiology software focused primarily on clinical image interpretation and from consumer wellness products that do not use structural neuroimaging. The available comparable-company records do not identify distinct external competitors, so a precise peer ranking is not possible. Within its category, BrainKey appears differentiated by translating complex anatomical measurements into longitudinal, user-facing insights while also describing applications for physicians and neurological care. The platform’s value proposition therefore depends on clinical validation, integration with imaging workflows, and demonstrating that personalized brain-health outputs produce actionable outcomes beyond standard MRI reporting.

BrainKey’s trajectory shows an early-stage progression from formation and initial financing into a more specialized brain-health platform. The company was founded on Apr 1, 2018, raised a $200,000 pre-seed round on Aug 1, 2018 from Amino Capital, Soma Capital, and Y Combinator, and recorded a seed round on Mar 18, 2019 involving Y Combinator, Joyance Partners, and Social Starts. A convertible note followed on Dec 1, 2021 with Longevitytech.fund, bringing disclosed total funding to $200,000 because no amount is recorded for the later rounds. Product development expanded beyond basic MRI analysis to include 3D anatomical visualization, brain-volume measurement, estimated brain age, genetic-data analysis, and personalized nutrition, exercise, and lifestyle recommendations. The current employee count remains in the one-to-ten range, and there are no documented hiring announcements or layoffs. The central inflection points are therefore technical scope and financing continuity, not demonstrated headcount or revenue acceleration.